**Description**

**A COMPOSITION FOR THE TREATMENT OF ARTHROPATHY DERIVATIVES**

**Technical Field**

The invention relates to a composition formed for the treatment of arthropathy derivatives.

**State of the Art**

Arthropathy is a general term referring to any joint disease. Inflammation of the joints (arthritis) and the degenerative processes (arthrosis), articular rheumatism and some other joint diseases (e.g. the joint diseases developing in relation to the diseases of the neural centers or peripheral nerves) are included by this term.

According to the state of the art, the invention no. WO 2000/001386 with classification "A61K 31/47" entitled "Farnesyl protein transferase inhibitors for treating arthropathies" is concerned with the finding that farnesyl protein transferase inhibitors are useful for preparing a pharmaceutical composition for treating arthropathies such as rheumatoid arthritis, osteoarthritis, juvenile arthritis, and gout.

Further, according to the invention no. EP1585728B1 entitled "Imino acid derivatives for use as inhibitors of matrix metalloproteinases", the compounds of formula (I) are useful for preparing drugs used in the prophylaxis and therapy of diseases which are associated with an increased matrix metalloproteinase activity. Examples of such diseases are degenerative articular diseases such as osteoarthroses, spondyloses, chondroporosis after articular trauma or prolonged joint immobilization after meniscus or patella injuries or rupture of a ligament, or a disease of the connective tissue such as collagenoses, periodontal diseases, defective wound healing, or a chronic diseases of the locomotor system such as inflammatory, immunologically or metabolically mediated acute or chronic arthritides, arthropathies, myalgias or disorders of the bone metabolism or an ulceration, atherosclerosis or stenosis or an inflammatory disease or a tumor disease, tumor metastatic spread, cachexia, anorexia or septicaemic shock.

Further, the invention no. EP1583525B1 entitled "Use of porphyrin synthesis substances in combination with salicylates and antioxidants for use in phototherapy to cure skin and/or articulation diseases" encompasses the use of porphyrin synthesis substances (in particular aminolevulinic acid) in combination with salicylates and with antioxidants (such as ascorbic acid) when a phototherapy is carried out (with a light emission whose wavelength ranges from 400 to 700 nm) for treating psoriasis or inflammatory processes (for instance on the skin and/or articulations of mammalians and human beings, in particular for curing arthritis, simple psoriasis, arthropathic psoriasis and neuropathies such as a carpal tunnel syndrome or Morbus Bechterew).

As a result, the presence of the need for a composition for treating the arthropathy derivatives and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

**Object of the Invention**

In order to eliminate the disadvantages of the state of the art, an object of the invention is to enable the respective components to trigger the osteoblast formation.

Another object of the invention is to increase the igf-1 receptor sensitivity in the bone tissues and to increase igf-1 level.

Another object of the invention is to suppress cox-2 and pge-2 and nf-kappaB pro-inflammatory cytokines.

In order to achieve the aforesaid advantages, the invention is a composition for the treatment of the arthropathy derivatives, said composition being obtained by the components selected from the group comprising 10b-​dimethoxy-​3,​4a,​7,​7-dimethyl-​1-​oxo-​3-​vinyldodecahydro-​1H-​benzo[f]chromen-​5coumaro​yl leucinate, 7-alpha-(3β,25R)-spirost-6-en-3-triol, 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 7-trimethoxy-diosgenin, 6-hexafluorodioscin that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.

**Detailed Description of the Invention**

The invention is a composition formed for the treatment of arthropathy derivatives. The respective components trigger the osteoblast formation, increase the igf-1 receptor sensitivity in the bone tissues and increase igf-1 level, and suppress cox-2 and pge-2 and nf-kappaB pro-inflammatory cytokines.

The composition according to the invention contains 10b-​dimethoxy-​3,​4a,​7,​7-dimethyl-​1-​oxo-​3-​vinyldodecahydro-​1H-​benzo[f]chromen-​5coumaro​yl leucinate, 7-alpha-(3β,25R)-spirost-6-en-3-triol, 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 7-trimethoxy-diosgenin, 6-hexafluorodioscin.

Said composition is obtained by a mixture of the aforesaid components according to the following ratios by weight:

22-10% 10b-​dimethoxy-​3,​4a,​7,​7-dimethyl-​1-​oxo-​3-​vinyldodecahydro-​1H-​benzo[f]​chromen-​5coumaro​yl leucinate,

8-20% 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one,

3-27% 7-alpha-(3β,25R)-spirost-6-en-3-triol,

11-8% 7-trimethoxy-diosgenin,

56-35% 6-hexafluorodioscin

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the use of said composition for treating the arthropathy derivatives and the manufacture thereof for this purpose.

**CLAIMS**

1. A composition for the treatment of the arthropathy derivatives, said composition being obtained by the components selected from the group comprising 10b-​dimethoxy-​3,​4a,​7,​7-dimethyl-​1-​oxo-​3-​vinyldodecahydro-​1H-​benzo[f]chromen-​5coumaro​yl leucinate, 7-alpha-(3β,25R)-spirost-6-en-3-triol, 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 7-trimethoxy-diosgenin, 6-hexafluorodioscin that are used individually or in combinations.
2. A composition according to Claim 1 characterized in that it comprises 22-10% by weight 10b-​dimethoxy-​3,​4a,​7,​7-dimethyl-​1-​oxo-​3-​vinyldodecahydro-​1H-​benzo[f] chromen-​5coumaro​yl leucinate.
3. A composition according to Claim 1 characterized in that it comprises 8-20% by weight 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one.
4. A composition according to Claim 1 characterized in that it comprises 3-27% by weight 7-alpha-(3β,25R)-spirost-6-en-3-triol.
5. A composition according to Claim 1 characterized in that it comprises 11-8% by weight 7-trimethoxy-diosgenin.
6. A composition according to Claim 1 characterized in that it comprises 56-35% by weight 6-hexafluorodioscin.
7. Use of the components according to Claims 1 to 6 obtained individually or in combinations from the group consisting of 10b-​dimethoxy-​3,​4a,​7,​7-dimethyl-​1-​oxo-​3-​vinyldodecahydro-​1H-​benzo[f]​chromen-​5coumaro​yl leucinate, 7-alpha-(3β,25R)-spirost-6-en-3-triol, 3,7-bis(2-hydroxyethyl)-3,5-trihydroxy-2-(4-epoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyren-4-one, 7-trimethoxy-diosgenin, 6-hexafluorodioscin **for the manufacture of a composition for treating the arthropathy derivatives**.

**ABSTRACT**

**A COMPOSITION FOR THE TREATMENT OF ARTHROPATHY DERIVATIVES**

The invention relates to a composition formed for the treatment of arthropathy derivatives.

No figure.